Although Patoulias et al. [8] reported that GLP-1 agonists are more efficacious than SGLT-2 inhibitors at improving glycemic control and HbA1c levels in patients with type 2 diabetes (mean difference = −0.38; 95% CI = −0.55, −0.22), the small number of studies included in that analysis limited the significance of those results. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.